During the corresponding time, Orthofix Medical Inc recorded a revenue increase by 1.51 % year on year, sequentially revenue fell by -10.8 %. While revenue at the Orthofix Medical Inc 's corporate clients
Orthofix Medical Inc's Comment on Sales, Marketing and Customers
The Company serves geographically dispersed customers with diversified end users, which limits concentration of credit risk related to accounts receivable. It has a collaborative arrangement with MTF Biologics ("MTF") and incurs research and development expenses related to this partnership. No other specific market segments or customers are identified.
Navigating the Storm: Orthofix Medical Faces Legal Turmoil with Class Action LawsuitIn an unfolding legal narrative that has captured the attention of investors and financial markets alike, Orthofix Medical Inc. (NASDAQ: OFIX) finds itself entangled in a class action lawsuit that not only questions its management practices but also severely impacts its stock valuation. As the company braces itself for upcoming legal battles, investors are urged to take action before significant deadlines approach. The Legal Battle UnveiledThe lawsuit filed by Holzer and Holzer, LLC, and further endorsed by Rosen Law Firm, stands at the center of Orthofix s current crisis. Accusations against the company are severe, alleging...
In a recent notification, Levi and Korsinsky, LLP announced the filing of a securities class action on behalf of investors in Orthofix Medical Inc. (Orthofix or the Company). The case, filed on September 5, 2024, targets the healthcare company s lackluster financial performance and its impact on shareholders. This development comes in a tumultuous period for the company, marred by significant financial losses and subpar return on investment (ROI).Orthofix Medical Inc. has encountered challenging times, culminating in a cumulative net loss of $136 million over the course of the twelve months ending in the third quarter of 2023. This financial downturn has led to a negative return on investment (ROI) of -20.4...
Orthofix Medical Inc., a leading global spine and orthopedics company, has recently revealed their preliminary unaudited net sales results for the fourth quarter and full-year 2023. The company showcased outstanding growth, achieving a significant increase in net sales on both reported and constant currency bases. This article will outline the facts and assess the impact of these remarkable figures on Orthofix Medical Inc.Orthofix Medical Inc. has reported preliminary unaudited fourth quarter net sales of approximately $200.3 million for 2023, representing an impressive increase of 63.8% on a reported basis and 62.8% on a constant currency basis compared to the same period in 2022. Furthermore, for the full ...
Orthofix Medical Inc’s Comment on Sales, Marketing and Customers
The Company serves geographically dispersed customers with diversified end users, which limits concentration of credit risk related to accounts receivable. It has a collaborative arrangement with MTF Biologics ("MTF") and incurs research and development expenses related to this partnership. No other specific market segments or customers are identified.
Sources:
Orthofix Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Orthofix Medical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Orthofix Medical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
29.39 %